Page 1

HIV in Europe

Working Together for Optimal Testing and Earlier Care Copenhagen 2012 Conference

Evaluation Report

HIV in Europe Copenhagen 2012 Conference 19 - 20 March 2012 University of Copenhagen

www.hivineurope.eu


Content Overall evaluation................................................................................................................................. 4 Plenary Sessions.................................................................................................................................. 6 Plenary 1: Opening Session............................................................................................................. 6 Plenary session 2: Access to earlier testing and care...................................................................... 7 Plenary session 3: Late presenters and the undiagnosed............................................................... 8 Plenary session 4: Discussing testing strategies.............................................................................. 8 Closing plenary: HIV in Europe – the way forward......................................................................... 9 Parallel Sessions.................................................................................................................................. 9

3


Overall evaluation The overall evaluation of the HIV in Europe conference, which was attended by 323 people, was very positive, with 93% of respondents, out of 90 participants responding, evaluating the conference as good or excellent. This is supported by 96% of respondents scoring that the conference met or exceeded their expectations.

4

Some excellent suggestions were made on conference content. For example, even though quite a considerable amount of time was spent on discussions and poster sessions, these two topics had the highest score of “too little time spent on topic�. The feedback presentations summarising each day were appreciated as were the parallel sessions. Participants noted in their evaluation that the conference covered the main topics and issues related to HIV testing in Europe Feedback regarding future work and conferences suggested having more peer-to-peer education, skills building sessions, round table discussion on realities on the ground, hands on sharing of experiences and workshop discussions with a smaller number of people. In this report we present all the data from the evaluation forms completed by 90 participants. Each section has a graphical overview of the evaluation scores, with those above 0 (blue and red) being good/excellent or extremely/very informative/useful and those below 0 being fair/poor or somewhat/not at all informative/useful (green and purple). Overall, how would you rate the entire meeting?

Overall evaluation Overall, how would you rate the entire meeting?

-10

0 Good

10 Excellent

20 Fair

30 Poor

40

50

60

70

80


How appropriate was the time spent on each of the following agenda items?

How appropriate was the time spent on each of the following agenda items? Parallel Sessions Plenary Sessions Poster Sessions Discussions

5

Social/Networking Opportunities -20

-10

0

too much

10 just right

20

30

40

50

60

70

too little

Overall, how did the meeting meet your expectations?

Expectations met?

Overall, how did the meeting meet your expectations?

-10 Met ExpectatuĂ­ons

0

10

20

Exceeded expectations

30

40

50

Below Expectations

60

70

80

90


Plenary Sessions Plenary 1: Opening Session

Opening Session Welcome to HIV in Europe Copenhagen 2012 Conference The role of WHO in optimal testing and earlier care Earlier testing and care on the European agenda

6

The role of ECDC in optimal testing and earlier care Key note speech European Commission Welcome note for Copenhagen University -40 Very Informative/Useful

-30

Extremely Informative/Useful

-20

-10

0

10

Somewhat Informative/Useful

20

30

40

50

60

Not at all Informative/Useful

The session gave a good overview of the situation and difference in Western and Eastern Europe. Barriers for implementation of new strategies were discussed as were new perspectives and paradigms of testing with less pre-test counseling in some settings. Comments to the presentation of estimating HIV prevalence were positive and it was recommended that this topic would need a seminar in itself to go into details. The initiative should continue to discuss with ECDC how to further inform the research agenda on this topic and disseminate and implement available methods.


Plenary session 2: Access to earlier testing and care

Access to earlier testing and care Key issues for HIV testing in Europe HIV testing guidelines in Europe and linkage to care: need for implementation - Western Europe perspective

7

Challenges in earlier HIV testing and linkage to care among people who inject drugs HIV testing and counseling in EECA: entry point for curbing the HIV epidemic Estimating HIV prevalence in European Countries -30

-20

-10

0

10

20

Very Informative/Useful

Extremely Informative/Useful

Somewhat Informative/Useful

Not at all Informative/Useful

30

40

50

60

70

The session gave a good overview of the situation and difference in Western and Eastern Europe. Barriers for implementation of new strategies were discussed as were new perspectives and paradigms of testing with less pre-test counseling in some settings. Comments to the presentation of estimating HIV prevalence were positive and it was recommended that this topic would need a seminar in itself to go into details. The initiative should continue to discuss with ECDC how to further inform the research agenda on this topic and disseminate and implement available methods.


Plenary session 3: Late presenters and the undiagnosed

Late presenters and the undiagnosed Guidance on Indicator Condition-Guided HIV testing: Presentation of draft guidance document Characteristics of the epidemiology and temporal trends of late presenters in Europe

8

An assessment of the approaches to evaluating costeffectiveness of HIV screening strategies Keynote speech: Danish Acting minister for Health -40 -30 -20 -10

0

10

20

Very Informative/Useful

Extremely Informative/Useful

Somewhat Informative/Useful

Not at all Informative/Useful

30

40

50

60

Comments to the session were mixed, from excellent and interesting to too technical or lacking in sufficient data. The indicator guidance document stimulated an interesting debate and will be one of the key focus areas of the initiative in the coming years – both in implementation and in supporting discussion on how much pre-test counselling is needed, that became one of the key discussion points of the conference. Another key discussion point following the presentation was on the importance of cost-effectiveness studies as important to political advocacy, thus needing to be part of the testing agenda. Plenary session 4: Discussing testing strategies

Discussing testing strategies Diagnostics/testing/regulations/incidence: US perspective A model of the MSM epidemic in the UK: implications for understanding the impact of condom use and ART in influencing incidence People Living with HIV Stigma Index: Findings from Estonia The COBATEST Project: Survey on Community?Based Testing Services in Europe -40 Very Informative/Useful

Extremely Informative/Useful

-30

-20

-10

0

Somewhat Informative/Useful

10

20

30

40

50

60

Not at all Informative/Useful

The two technical presentations were more positively evaluated than the two community presentations. It was mentioned that the modelling presentation could be a good workshop theme. The community presentations could also be better suited for parallel sessions. It seems that many of the topics discussed in plenary sessions during the conference could benefit from more focused workshop sessions at future meetings.


Closing plenary: HIV in Europe – the way forward

HIV in Europe - the way forward HIV testing and counseling services in Ukraine: what else should be done? The impact and the outcome of the EP Resolution of 20 November 2008? 'HIV/AIDS: early diagnosis and early care' - Italy as a case Parallel discussion

9 -40

Very Informative/Useful

Extremely Informative/Useful

-30

-20

-10

0

Somewhat Informative/Useful

10

20

30

40

Not at all Informative/Useful

Parallel Sessions Parallel Sessions Lessons learned in novel HIV testing strategies and programmes Characteristics of PLHIV who present late for care and missed opportunities for earlier diagnosis HIV testing among key populations New testing diagnostic technologies Cost effectiveness of HIV Testing HIV testing and the continuum of HIV care -20 Very Informative/Useful

Extremely Informative/Useful

-10

0

10

Somewhat Informative/Useful

20

30

40

50

60

Not at all Informative/Useful

The parallel sessions were positively evaluated by the majority and worked very well with chairs moderating and ensuring time for discussion. The high quality and interest in submitting abstracts to the conference, filing up 6 parallel sessions as well as the poster sessions was considered an important outcome of the conference and something to be repeated.


gonist* fra GOLD-stadium II4 Main Sponsor

event® (salmeterol) – Langtidsvirkende beta-2-agonist (12 timer).

symptomatisk tillægsbehandling ved reversibel luftvejsostruktion hos patienter med astma, under natlig astma, hvor tilstrækkelig kontrol ikke opnås med inhalationssteroider i henhold ældende retningslinjer for behandling. Behandling af kronisk obstruktiv lungesygdom (KOL). byggelse ved anstrengelsesudløst astma. The conference has received funding from the European Commission under the Health Programme 2008-2013. However,

the sole responsibility for theherunder study lieslaktose with the author andmælkeproteiner). the European Commission is not responsible for any use that rfølsomhed over for indholdsstofferne (indeholder may be made of the information contained therein

ndelige: Hovedpine, tremor, palpitationer, muskelkramper.

Additional unrestricted funding provided by:

: 50 mikrogram 2 gange dagligt. Platinum os®, 50 µg/dosis, 60 doser, 340,00 kr.partner lationsspray, 25 µg/dosis, 120 doser, 278,60 kr.

Gold partner

saktuel pris findes på www.medicinpriser.dk.

af SPIRIVA® (tiotropium) og Serevent ® (salmeterol) undersøgtes over et år i et direkte sammenhavde moderat til svær KOL. Primær effektparameter: SPIRIVA® (tiotropium) udsatte signifikant ktion.

Boehringer Ingelheim Danmark A/S Strødamvej 52 · 2100 København Ø Telefon 39 15 88 88 · Telefax 39 15 89 89

Endorsement from:

04/11/11 09.20

AIDS Action Europe www.aidsactioneurope.org

Faculty of Health Sciences, University of Copenhagen www.cphiv.dk www.sund.ku.dk

European AIDS Treatment Group (EATG) www.eatg.org

Printed in Denmark by Kandrup

ste side.

Silver partners

HIV in Europe 2012 Evaluation Report  

HIV in Europe 2012 Evaluation Report

Read more
Read more
Similar to
Popular now
Just for you